Mar 10, 2022 7:05am EST IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022
Mar 09, 2022 7:05am EST IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022
Jan 12, 2022 7:05am EST IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL
Dec 21, 2021 7:05am EST IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts
Dec 20, 2021 7:05am EST IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility
Dec 02, 2021 7:05am EST Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress
Nov 30, 2021 7:05am EST IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer
